At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 420 enrolled
Drug / intervention
insulin degludec/liraglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus. DUALTM IX - Add-on to SGLT2i
In Brief
A Phase 3 clinical trial evaluating insulin degludec/liraglutide and insulin glargine for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 420 participants across 88 sites in 11 countries.
Detailed Summary
This trial is conducted globally. The aim of this trial is comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i (sodium-glucose cotransporter 2 inhibitors) in subjects with type 2 diabetes mellitus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesArgentina, Canada, Finland, Hungary, India, Russia, Slovakia, Slovenia, Spain, Switzerland, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 2016
Enrollment StartMay 2016
Primary CompletionSep 2017
Study CompletionOct 2017
TodayJul 2026
First PostedMay 16, 2016
Enrollment StartMay 23, 2016
Primary CompletionSep 26, 2017
Study CompletionOct 23, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.1 years ago
Interventions
insulin degludec/liraglutidedrug
IDegLira will be given subcutaneously ( s.c., under the skin) once daily.
insulin glarginedrug
IGlar will be given subcutaneously ( s.c., under the skin) once daily.